15th January 2021 Missed our free GatewayC webinar on Diagnosing Ovarian Cancer? Watch our recording here. In this webinar, GatewayC met Professor Gordon Jayson, Professor of Medical Oncology at The Christie NHS Foundation Trust, who answered key questions from our...
Cancer Keys: Faecal Calprotectin
Latest from the Blog
NEW COURSE: Managing Physical Effects
Tuesday 5th January 2021 We are delighted to announce that the new Managing Physical Effects course is now available on GatewayC. According to Macmillan, at least 1 in 4 patients will experience consequences of their cancer or treatment that affect their quality of...
Related Posts
Cancer Keys: Thresholds for a Positive FIT Test in Symptomatic Patients
Potential pitfall: A negative bowel screening test should not be used to make decisions about referral in a symptomatic patient. Sensitivity levels have been set very differently for screening and symptomatic Faecal Immunochemical Tests (FIT). Helpful hint: The...
Cancer Keys: Chronic Myeloid Leukaemia and Fatigue
Potential pitfall: Fatigue is a common presenting problem in primary care, and yet it is important to remember that fatigue can represent a more serious condition. Many patients with chronic myeloid leukaemia (CML) have few or no symptoms at the time they are...

Potential pitfall:
Faecal calprotectin testing is an incredibly sensitive investigation for detecting the presence of inflammation. It is raised in a wide variety of conditions including malignancy, inflammatory bowel disease and alcohol misuse. It is therefore not good at defining either the site or the cause of inflammation.
Helpful hint:
The NICE DG11 guidance recommends faecal calprotectin testing as an option to support clinicians with the differential diagnosis of inflammatory bowel disease (IBD), or irritable bowel syndrome (IBS), in adults with recent onset lower gastrointestinal symptoms for whom specialist assessment is being considered, if:
-
- cancer is not suspected, having considered the risk factors (for example, age) described in the NICE guideline on suspected cancer and
- appropriate quality assurance processes and locally agreed care pathways are in place for the testing.
Cancer Keys are brought to you by GatewayC.
Download this Cancer Key here
Read the NICE NG12 guidance here
Access GatewayC’s Faecal Immunochemical Test (FIT) course here

Latest from the Blog
Meet the specialists: diagnosing ovarian cancer Q&A
15th January 2021 Missed our free GatewayC webinar on Diagnosing Ovarian Cancer? Watch our recording here. In this webinar, GatewayC met Professor Gordon Jayson, Professor of Medical Oncology at The Christie NHS Foundation Trust, who answered key questions from our...
NEW COURSE: Managing Physical Effects
Tuesday 5th January 2021 We are delighted to announce that the new Managing Physical Effects course is now available on GatewayC. According to Macmillan, at least 1 in 4 patients will experience consequences of their cancer or treatment that affect their quality of...
Related Posts
Cancer Keys: Thresholds for a Positive FIT Test in Symptomatic Patients
Potential pitfall: A negative bowel screening test should not be used to make decisions about referral in a symptomatic patient. Sensitivity levels have been set very differently for screening and symptomatic Faecal Immunochemical Tests (FIT). Helpful hint: The...
Cancer Keys: Chronic Myeloid Leukaemia and Fatigue
Potential pitfall: Fatigue is a common presenting problem in primary care, and yet it is important to remember that fatigue can represent a more serious condition. Many patients with chronic myeloid leukaemia (CML) have few or no symptoms at the time they are...